How is mazdutide dosed?
Mazdutide is dosed by China’s NMPA label for Xinermei (信尔美): 2,000 mcg (2 mg) by subcutaneous injection once weekly for 4 weeks, then 4,000 mcg (4 mg), rising if needed and tolerated to 6,000 mcg (6 mg) from week 9, with 4,000 mcg (4 mg) as the fallback maintenance dose. Mazdutide has no FDA approval, and no clinic publishes a dose of its own.
Topic: Reading mazdutide’s Chinese NMPA label directly, since no FDA label exists
Audience: Anyone comparing a mazdutide dose figure against its actual label or trial source
Reading time: 8–10 minutes
Approved in China — NOT approved in the US
Mazdutide has not been approved by the FDA, EMA, or any regulatory body outside China. It has been approved by China’s National Medical Products Administration (NMPA) under the brand name Xinermei, for chronic weight management and for glycemic control in type 2 diabetes. This page reads that Chinese label as its primary source — the same way Prof. Peptide reads FDA labels for approved US brands — and states plainly, throughout, that no US approval exists.
What mazdutide is, and where it’s approved
Mazdutide is a glucagon-like peptide-1 (GLP-1) and glucagon receptor (GCG) dual agonist, given once weekly by subcutaneous injection, developed by Innovent Biologics; its US phase 2 trial was funded by Eli Lilly and Company. It is approved in China under two separate NMPA labels, both under the brand name Xinermei (信尔美): one for chronic weight management, approved per the label’s own 核准日期 (approval date) field of June 24, 2025 (approval numbers 国药准字H20250036, H20250037, and H20250038 for the 2 mg, 4 mg, and 6 mg strengths respectively); and a second for glycemic control in adults with type 2 diabetes, approved September 16, 2025. Innovent’s own press releases state June 27, 2025 and September 19, 2025 for the two approvals — close to, but not identical to, the labels’ own dates, which this page reports as primary.
Outside China, mazdutide has no approved product and no FDA or EMA filing decision. The mazdutide profile covers the mechanism and broader research areas in more depth; this page exists specifically to read the NMPA label’s own dosing schedule and the GLORY trial doses side by side.
What the NMPA label specifies
The table below is mazdutide’s recommended dosage as stated in the 用法用量 (Dosage and Administration) section of the weight-management NMPA package insert, read directly from the manufacturer’s own published PDF. The type 2 diabetes label carries the identical titration table.
| Step | Dosage | As specified by the label |
|---|---|---|
| Starting dose | 2,000 mcg (2 mg) once weekly | Weeks 1–4 (titration starting dose). |
| First increase | 4,000 mcg (4 mg) once weekly | Weeks 5–8. |
| Maintenance | 4,000 mcg (4 mg) or 6,000 mcg (6 mg) once weekly | Week 9 onward: 6,000 mcg (6 mg) if further weight or glycemic improvement is needed, after at least 4 weeks on the current dose; 4,000 mcg (4 mg) may be used as maintenance if 6,000 mcg (6 mg) is not tolerated. |
The label states a four-tier missed-dose rule (如发生遗漏用药), counted from the last dose given: missed by up to 2 days (within 9 days of the last dose), the missed dose is given as soon as possible and the next dose on its original date; missed by 2 to 7 days (9 to 14 days since the last dose), the missed dose is given as soon as possible and the once-weekly schedule is recalculated from that date; missed by 7 to 21 days (14 to 28 days since the last dose), the dose steps down to the previous dose in the table and titration restarts; missed by more than 21 days (more than 28 days since the last dose), the dose steps down to the starting dose and the full titration table restarts.
Both labels carry a boxed warning (警告) on thyroid C-cell tumors, like FDA-approved GLP-1-class labels; whether mazdutide causes them in humans has not been determined, and it is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Dosage forms and strengths (规格) list single-use pre-filled auto-injector pens at 2 mg, 4 mg, and 6 mg per 0.5 mL, each given by subcutaneous injection once weekly. The peptide dosage calculator works out how much bacteriostatic water to add to a research-grade vial and how many syringe units a given amount takes. It does not set a dose.
What do clinics report?
No clinic was found publishing a mazdutide dose or protocol after searching 207 clinic sources in Prof. Peptide’s clinic registry and a web search. Of the eight largest US peptide clinics, one has a page on mazdutide and none publishes a dose or prescribes it, since mazdutide has no US approval. The label above and the trials below are the only dosing sources.
The one clinic page on mazdutide, in Singapore, describes it as a dual GLP-1 and glucagon weight-loss injection approved in China but not in Singapore, and reports the trials rather than its own patients: side effects similar to other GLP-1-based drugs, namely nausea, vomiting, diarrhea, reduced appetite and injection-site reactions, mostly early in treatment and mild to moderate. The mazdutide profile’s dosing section carries the same clinic record.
Compounding and research-grade mazdutide
Mazdutide has no US-approved product, so there is neither a US branded version nor a lawful US pharmacy-compounded version of one — its NMPA approval in China does not change that.
No published FDA warning letter names mazdutide. FDA’s own warning letter on GLP-1 compounding (“GLP-1 Solution,” reference 715883, dated September 9, 2025) names retatrutide, semaglutide, and tirzepatide specifically — not mazdutide. This page instead applies section 503A’s published criteria to mazdutide directly: a bulk drug substance is eligible for compounding only if it complies with a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA’s 503A bulks list. Checked directly against FDA’s own 503A and 503B bulk drug substance list pages on the date this page was built, “mazdutide” appears on neither list, in any category. Mazdutide has no USP or NF monograph and is not a component of any FDA-approved drug. Approval by a foreign regulator, including China’s NMPA, does not satisfy any of the three 503A conditions, which turn on US regulatory status specifically.
Research-grade mazdutide, of the kind sold by the vendors Prof. Peptide tracks elsewhere on this site, is not a compounded drug product and not a branded product in the US — those categories don’t apply to it at all here. It is sold labeled for laboratory research use, not for human administration, and it is not dispensed against a prescription.
What the trials administered
Five published randomized trials report mazdutide doses. Two underlie the NMPA weight-management approval and the label’s dosing table: GLORY-1, which supplies the 4,000 mcg (4 mg) and 6,000 mcg (6 mg) doses the label recommends, and GLORY-2, which tested a higher 9,000 mcg (9 mg) dose not part of the approved label. DREAMS-1 and DREAMS-2, in type 2 diabetes, used the label’s 4,000 and 6,000 mcg (4 and 6 mg) (4 and 6 mg) doses. A US phase 2 trial tested up to 16,000 mcg (16 mg). Doses above 6,000 mcg (6 mg) are trial doses only. Each trial is graded against Prof. Peptide’s standing citation convention: a claim is attributed when it resolves to a named, checkable source. All five grade as attributed, peer-reviewed publications.
GLORY-1: Phase 3, Obesity/Overweight
NCT05607680Ji L, Jiang H, Bi Y, et al. N Engl J Med. 2025;392(22):2215–2225.
Design: Phase 3, double-blind, placebo-controlled trial in China, in adults aged 18–75 with a BMI of 28 or higher, or 24 to under 28 with at least one weight-related coexisting condition. Coprimary endpoints (percentage body-weight change and ≥5% weight reduction at week 32) used a treatment-policy estimand.
Arms: 610 participants randomized 1:1:1 to once-weekly subcutaneous mazdutide 4,000 mcg (4 mg), mazdutide 6,000 mcg (6 mg), or placebo, for 48 weeks.
Endpoint reported: Body-weight change at week 48: −11.00% (4,000 mcg, 4 mg) and −14.01% (6,000 mcg, 6 mg), versus +0.30% (placebo). At week 32: −10.09% and −12.55% versus +0.45% (placebo); 73.9%, 82.0%, and 10.5% respectively achieved ≥5% weight reduction (P<0.001 for all comparisons with placebo).
Adverse events reported at these doses: The most frequently reported adverse events were gastrointestinal, mostly mild to moderate. Adverse events leading to discontinuation: 1.5% (4,000 mcg, 4 mg), 0.5% (6,000 mcg, 6 mg), 1.0% (placebo).
Attributed: published in a peer-reviewed journal (NEJM, 2025), registered with a checkable NCT number, phase/N independently confirmed against the ClinicalTrials.gov record. This is the trial underlying the NMPA's weight-management approval. Abstract re-read November 6, 2026.
GLORY-2: Phase 3, Moderate-to-Severe Obesity
NCT06164873Gao L, Jiang H, Cai H, et al. JAMA. 2026;336(5):377–388.
Design: Phase 3, double-blind, placebo-controlled trial in China, in adults with or without type 2 diabetes and a BMI of 30 or higher, conducted at 27 hospitals from December 2023 to November 2025. Coprimary endpoints (percentage body-weight change and ≥5% weight reduction at week 60) were analyzed in participants receiving at least one dose.
Arms: 461 participants received treatment (307 mazdutide, 154 placebo) of 462 randomized 2:1 to once-weekly subcutaneous mazdutide 9,000 mcg (9 mg) or placebo, for 60 weeks.
Endpoint reported: Body-weight change at week 60: −16.65% (mazdutide) versus −1.50% (placebo), between-group difference −15.15% (95% CI −17.22 to −13.09, P<0.001). 84.3% of the mazdutide group achieved ≥5% weight reduction, versus 33.1% on placebo.
Adverse events reported at these doses: Adverse events leading to discontinuation: 2.9% (mazdutide) versus 0% (placebo). The most common adverse events were vomiting (53.1% vs. 1.3%), nausea (46.9% vs. 3.2%), and diarrhea (39.4% vs. 6.5%), most mild to moderate.
Attributed: published in a peer-reviewed journal (JAMA, 2026), registered with a checkable NCT number, phase/N independently confirmed against the ClinicalTrials.gov record. An earlier topline press release reported different figures (−18.55%/−3.02%, N=462) before peer review; the published JAMA figures above are reported as primary, since they are the checked, final analysis. Abstract re-read November 6, 2026.
US phase 2: Obesity/Overweight without Type 2 Diabetes
NCT06124807Hsia SH, Bays HE, Billings LK, et al. Lancet Diabetes Endocrinol. 2026;14(11):879–893. Funded by Eli Lilly and Company.
Design: Randomized, double-blind, placebo-controlled phase 2 trial at 24 centers in the USA, in adults aged 18–75 without type 2 diabetes and with a BMI of 30 or higher, or 27 to under 30 with at least one weight-related comorbidity. Primary endpoint: percentage change in bodyweight at 32 weeks.
Arms: 179 participants randomized to once-weekly subcutaneous mazdutide 3,000–6,000 mcg (3–6 mg; 32 participants), 10,000 mcg (10 mg; 48), 16,000 mcg (16 mg; 51) or placebo (48) for 48 weeks. The 3,000–6,000 mcg (3–6 mg) arm stayed at 3,000 mcg (3 mg) from week 4 to week 32, then rose to 6,000 mcg (6 mg).
Endpoint reported: Bodyweight change at 32 weeks: −7.3% (3,000–6,000 mcg, 3–6 mg), −15.6% (10,000 mcg, 10 mg) and −18.1% (16,000 mcg, 16 mg), versus −0.9% on placebo; further reductions at 48 weeks.
Adverse events reported at these doses: The most common adverse events were gastrointestinal, mostly mild to moderate. Discontinuation for adverse events was most frequent at 16,000 mcg (16 mg), 20%, mainly for gastrointestinal disorders.
Attributed: peer-reviewed (Lancet Diabetes Endocrinol, 2026), registered (NCT06124807, stated in the abstract). The doses above 6,000 mcg (6 mg) are trial doses, not part of China's label. Abstract read November 6, 2026.
DREAMS-1: Phase 3, Type 2 Diabetes vs Placebo
Zhu D, Zhao J, Cai H, et al. Nature. 2026;652(8108):174–180.
Design: Phase 3 trial in Chinese adults with type 2 diabetes not controlled by diet and exercise alone: mazdutide alone versus placebo, followed by a 24-week extension on mazdutide.
Arms: 320 participants randomized 1:1:1 to once-weekly subcutaneous mazdutide 4,000 mcg (4 mg), 6,000 mcg (6 mg) or placebo for 24 weeks.
Endpoint reported: HbA1c at week 24: −1.57% (4,000 mcg, 4 mg) and −2.15% (6,000 mcg, 6 mg) versus −0.14% (placebo).
Adverse events reported at these doses: The most common adverse events were diarrhea, decreased appetite and nausea, which the authors describe as consistent with GLP-1 receptor agonists.
Attributed: peer-reviewed (Nature, 2026). This trial program underlies the type 2 diabetes indication, whose label carries the same titration table. Abstract read November 6, 2026.
DREAMS-2: Phase 3, Type 2 Diabetes vs Dulaglutide
Guo L, Zhang B, Xue X, et al. Nature. 2026;652(8108):181–188.
Design: Randomized phase 3 trial in Chinese adults with type 2 diabetes on background oral anti-diabetic drugs, comparing mazdutide with dulaglutide.
Arms: 731 participants randomized 1:1:1 to mazdutide 4,000 mcg (4 mg), mazdutide 6,000 mcg (6 mg) or dulaglutide 1,500 mcg (1.5 mg) for 28 weeks.
Endpoint reported: HbA1c: both mazdutide doses were non-inferior and superior to dulaglutide, by a further −0.24% (4,000 mcg, 4 mg) and −0.30% (6,000 mcg, 6 mg); body weight fell by a further −3.78% and −5.76%.
Adverse events reported at these doses: The most common treatment-emergent adverse events were diarrhea, nausea and vomiting; gastrointestinal adverse events were more frequent with mazdutide than with dulaglutide.
Attributed: peer-reviewed (Nature, 2026). Abstract read November 6, 2026.
FAQ
Is mazdutide FDA-approved?
What is the NMPA-approved starting dose?
Do clinics publish a mazdutide dose?
What is the missed-dose rule?
What are the side effects at the label and trial doses?
Does mazdutide carry a boxed warning?
Can mazdutide legally be compounded in the US the way semaglutide or tirzepatide once were?
What category does research-grade mazdutide fall under?
References
- Innovent Biologics (信达生物制药苏州有限公司). 玛仕度肽注射液说明书 (Mazdutide Injection prescribing information) — weight-management indication, 核准日期 2025-06-24, 批准文号 国药准字H20250036/H20250037/H20250038. Re-read November 6, 2026. https://img.innoventbio.com/product/W10030842001.pdf
- Ji L, Jiang H, Bi Y, et al. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025;392(22):2215–2225. ClinicalTrials.gov NCT05607680. Abstract re-read November 6, 2026. https://clinicaltrials.gov/study/NCT05607680
- Gao L, Jiang H, Cai H, et al. Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA. 2026;336(5):377–388. ClinicalTrials.gov NCT06164873. Abstract re-read November 6, 2026. https://clinicaltrials.gov/study/NCT06164873
- Hsia SH, Bays HE, Billings LK, et al. Efficacy and safety of mazdutide in adults with obesity or overweight: a US-based, multicentre, phase 2, randomized, placebo-controlled clinical trial. Lancet Diabetes Endocrinol. 2026;14(11):879–893. ClinicalTrials.gov NCT06124807. Funded by Eli Lilly and Company. Abstract read November 6, 2026. https://pubmed.ncbi.nlm.nih.gov/42628555/
- Zhu D, Zhao J, Cai H, et al. Mazdutide versus placebo in Chinese adults with type 2 diabetes (DREAMS-1). Nature. 2026;652(8108):174–180. Abstract read November 6, 2026. https://pubmed.ncbi.nlm.nih.gov/41407859/
- Guo L, Zhang B, Xue X, et al. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes (DREAMS-2). Nature. 2026;652(8108):181–188. Abstract read November 6, 2026. https://pubmed.ncbi.nlm.nih.gov/41407860/
- Sire Clinic, Singapore (medically reviewed by Dr. Bosty Chan, MBChB, MRCS). Mazdutide in Singapore: what China’s new weight loss injection means for patients here. The clinic page is dated May 4, 2026; read November 6, 2026. The clinic describes the trials, not its own patients. https://thesire.sg/blog/mazdutide-singapore/
- U.S. Food and Drug Administration. Warning Letter: GLP-1 Solution, reference 715883, 2025-09-09 (names retatrutide, semaglutide, and tirzepatide; does not name mazdutide). https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/glp-1-solution-715883-09092025
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
- U.S. Food and Drug Administration. 503B Bulk Drug Substances List. https://www.fda.gov/drugs/human-drug-compounding/503b-bulk-drug-substances-list
Affiliate disclosure: Prof. Peptide earns a commission on purchases and sign-ups made through its links and codes, at no extra cost to the buyer. Commissions never decide which vendors are listed, how they are ranked or verified, or what Prof. Peptide concludes.
Related pages
- MazdutideMazdutide, a GLP-1 and glucagon receptor dual agonist approved in China as Xinermei: GLORY-1 and GLORY-2 weight results, the NMPA label dose, side effects, legal…
- How Is Ipamorelin Dosed? What Clinics Prescribe, and the IV TrialsClinics prescribe ipamorelin at 100 to 300 mcg by subcutaneous injection, or 100 to 400 mcg of each with CJC-1295, at bedtime.
- MOTS-c Dosage Chart: How Much MOTS-c Per Week Clinics PrescribeMOTS-c dosage as clinics publish it: 5,000–10,000 mcg (5–10 mg) per injection, 2–3 times a week, in 8–12 week cycles, with the range reported, a clinic dosage chart,…
- Guides — Practical Peptide Research ReferencesPractical reference guides for peptide research — injection technique, reconstitution math, syringe sizing, and research fundamentals.
Checked and updated
